European equities traded in the US as American depositary receipts were tracking lower late Wednesday morning, declining 0.93% to 1,450.69 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and furniture maker Natuzzi (NTZ), which advanced 14% and 11% respectively. They were followed by biopharmaceutical company Genfit (GNFT) and internet browser company Opera (OPRA), which rose 1.9% and 1.7% respectively.
The decliners from continental Europe were led by Spanish lender Banco Bilbao Vizcaya Argentaria (BBVA) and pharmaceutical company Novo Nordisk (NVO), which fell 2.1% and 1.8% respectively. They were followed by Dutch financial services company ING (ING) and petroleum refiner Equinor (EQNR), which were down 1.5% and 1.3% respectively.
From the UK and Ireland, the gainers were led by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company Bicycle Therapeutics (BCYC), which climbed 4.5% and 4.3% respectively. They were followed by biopharmaceutical companies Amarin (AMRN) and Adaptimmune Therapeutics (ADAP), which advanced 1.9% and 1.4% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and NuCana (NCNA), which dropped 6.1% and 2.9% respectively. They were followed by biotech firm Trinity Biotech (TRIB) and utilities company National Grid (NGG), which lost 2.7% and 2.4% respectively.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。